ache-in-6

AChE-IN-6 is an optimal multifunctional ligand that significantly inhibits AChE activity with IC50 values of 0.20 μM and 37.02 nM for EeAChE and HuAChE, respectively, and has anti-Aβ activity (IC50= 1.92 μM for self-induced Aβ1-42 aggregation, IC50= 1.80 μM for disaggregation of Aβ1-42 pro AChE-IN-6 has shown research potential in Alzheimer's disease.

AChE/BuChE-IN-6 (Compound 11f) is an inhibitor of AChE and BuChE, with IC50 values of 1.24 and 1.85 μg/mL, respectively. It exhibits strong DPPH radical scavenging activity (IC50 = 3.15 μg/mL). In vivo toxicity studies demonstrate that AChE/BuChE-IN-6 is safe, showing no significant differences in blood and biochemical parameters compared to controls, and no abnormalities in liver and kidney tissues. This compound shows potential for Alzheimer's disease research.

AChE/MAO-B-IN-6 (compound 3a) is a dual inhibitor of AChE and h-MAO-B, showing potential for the inhibition of Alzheimer's disease.

hAChE-IN-6 (compound 51) is a brain-penetrant acetylcholinesterase (AChE) inhibitor with an IC50 of 0.16 μM. It also inhibits human butyrylcholinesterase (hBuChE) and glycogen synthase kinase 3 beta (GSK3β), with IC50 values of 0.69 μM and 0.26 μM, respectively. Additionally, hAChE-IN-6 impedes the self-aggregation of tau protein and amyloid-beta 1-42 (Aβ1-42), making it useful for Alzheimer's disease (AD) research [1].

AChE-IN-60 (compound 6k) is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), with IC50 values of 27 nM and 43 nM, respectively. It also inhibits monoamine oxidase MAO-A and MAO-B, with IC50 values of 353 nM and 716 nM, respectively.

AChE-IN-62 (Compound 1) is a potent, mixed-type selective inhibitor of acetylcholinesterase (AChE) with an IC50 value of 0.421 μM. It effectively penetrates the blood-brain barrier and offers neuroprotective effects. Additionally, AChE-IN-62 inhibits the aggregation of Aβ1-42 with an IC50 of 44.64 μM. This compound also acts as an effective multi-target-directed ligand (MTDL) and is applicable in Alzheimer's disease research.

AChE-IN-63 (Compound 5AD) serves as a selective inhibitor of hAChE, exhibiting an IC 50 value of 0.103 μM. Moreover, it inhibits hBChE and hBACE-1 with IC 50 values of 10 μM and 1.342 μM, respectively. AChE-IN-63 is effective in inhibiting Aβ aggregation and preventing the formation and deposition of Aβ1-42. It can effectively penetrate the blood-brain barrier and is orally bioavailable. This compound is primarily utilized in research related to Alzheimer's disease [1].

AChE-IN-64 (compound C4), with an IC 50 of 36.9 µM, acts as an AChE inhibitor and is applicable in the study of cognitive disorders.

AChE-IN-65 (Compound DABA_1) serves as a mixed inhibitor of acetylcholinesterase (AChE), exhibiting a Ki of 556.4 μM against Electrophorus electricus AChE.

Nematicidal Agent 1 is an effective nematicide that binds to the pocket of acetylcholinesterase (AChE).

AChE-IN-68 (compound 2l) is an effective selective AChE inhibitor with an IC50 of 0.040 μM. It exhibits high blood-brain barrier permeability. This compound is utilized in research on neurodegenerative diseases, particularly Alzheimers disease.

AChE-IN-69 (compound 7o) is an effective AChE inhibitor with an IC50 of 1.67 µM, showing potential for Alzheimer's disease research.

BACE1-IN-15 (compound 4j) serves as an effective inhibitor of BACE1 (β-secretase), efficiently mitigating the copper-induced toxicity of Aβ, with an EC50 value of 0.68 μM.

AChE-IN-67 (compound 8n) is an effective AChE inhibitor with an IC50 of 0.033 μM, exhibiting activity comparable to Donepezil. It possesses high blood-brain barrier (BBB) permeability and is utilized in Alzheimers disease research.

AChE-IN-73 (compound 6), an insecticide, exhibits potent mosquito inhibitory capabilities, particularly against C. pipiens with an LC 50 of 78.0 mg/L. It demonstrates high affinity for acetylcholinesterase (AChE) and nicotinic acetylcholine receptors (nAChR), with respective binding energies of -8.11 kcal/mol and -6.27 kcal/mol.

AChE-IN-76 (compound 6) is an acetylcholinesterase inhibitor with an IC50 of 7.6 nM.

MAO-IN-6 (Compound 3f) is a reversible MAO-B inhibitor that can cross the blood-brain barrier, with an IC50 value of 0.09 μM. It also shows inhibitory activity against AChE and BChE, with IC50 values of 4.48 μM and 17.03 μM, respectively. MAO-IN-6 exhibits low cytotoxicity and is applicable in Alzheimer's disease research.

Insecticidal agent 21 (Compound 6) is an insecticide targeting Culex pipiens larvae with an LC50 of 0.4 μg/mL. It achieves multi-target neurotoxicity by inhibiting acetylcholinesterase (AChE) and simultaneously targeting other neural receptors, including nicotinic acetylcholine receptors (nAChR), voltage-gated sodium channels (VGSC), and γ-aminobutyric acid receptors (GABAAR). Insecticidal agent 21 shows potent insecticidal activity and can be utilized in the development of new insecticides to combat mosquito resistance to conventional agents.

Dual AChE-MAO B-IN-4 (compound 7) is a dual inhibitor of AChE and MAO-B, with IC50 values of 261 nM and 15 nM, respectively. It offers protection against oxidative damage induced by H2O2 and 6-OHDA in SH-SY5Y cells and can penetrate the central nervous system in a model simulating the blood-brain barrier. This compound is applicable in research on neurological disorders such as Alzheimer's disease (AD).

P11149, a derivative of Galanthamine, acts as a competitive, orally active, and selective AChE inhibitor with the ability to weakly penetrate the blood-brain barrier (BBB). It demonstrates selective inhibition, exhibiting an IC50 of 1.3 μM for rat BChE/AChE, and shows central cholinergic activity, behavioral efficacy, and safety. P11149 is utilized in Alzheimer's disease research[1].

1. Acetylshikonin exhibits weak cytotoxicity against human umbilical vein endothelial cells (HUVECs) with IC5 of over 2 microM, exhibits the antiangiogenic and antitumorigenic effects by suppressing proliferation and angiogenic factors. 2. Acetylshikonin inhibits the generation of NADPH oxidase complex in the activation of respiratory burst of PMNs, but does not directly inhibit the activity of NADPH oxidase already generated. 3. Certain shikonin derivatives(such as Acetylshikonin) act as modulators of the Nur77-mediated apoptotic pathway and identify a new shikonin-based lead that targets Nur77 for apoptosis induction. 4. Acetylshikonin, shikonin, and alkannin have accelerative effect on the proliferation of granulation tissue in rats. 5. Acetylshikonin has inhibitory effect on the edematous response is due neither to the release of steroid hormones from the adrenal gland nor to the glucocorticoid activity, but probably partly to the suppression of mast cell degranulation and partly to protection of the vasculature from mediator challenge. 6. Acetylshikonin induces apoptosis of hepatitis B virus X protein-expressing human hepatocellular carcinoma cells via endoplasmic reticulum stress.

AChE/hCA I/II-IN-1 (Compound 6) is a potent AChE/Hca inhibitor with IC50 values of 22.21, 60.79, and 66.64 nM for AChE, Hca Ⅰ, and Hca Ⅱ. AChE/hCA I/II-IN-1 can be used in glaucoma, Alzheimer's disease, and diabetes research[1].

Y13g is a potent inhibitor of Interleukin-6 (IL-6) and acetylcholinesterase (AChE), both significant targets in Alzheimer's Disease (AD) progression. Y13g reverses memory deficits induced by STZ and demonstrates histopathology similar to that of normal animals [1].

HDAC6-IN-6 (compound 6a) is a potent HDAC6 inhibitor with an IC50 value of 0.025 μM that can penetrate the BBB. It exhibits strong inhibitory activity against AChE and Aβ 1-42 self-aggregation with IC50 values of 0.72 and 3.0 μM, respectively. HDAC6-IN-6 also enhances neurite outgrowth without significant neurotoxicity [1].